Evidence map›Paper›PMID 30887058›Full record

ReviewDer Urologe. Ausg. A2019

[Influence of modern diagnostic methods on the treatment of nonmetastatic castration-resistant prostate cancer].

A Kretschmer, D Tilki

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Urologe. Ausg. A, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

A KretschmerUrologische Klinik und Poliklinik, Klinikum der Universität München, Ludwig-Maximilians Universität München, München, Deutschland.
D TilkiMartini-Klinik Prostatakrebszentrum, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland. d.tilki@uke.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Until 2018, patients with nonmetastatic castration-resistant prostate cancer (nmCRPC/M0CRPC) did not have a generally acknowledged standard of care therapy. As a result, these patients were often managed in a nonstandardized individual fashion and comparative analyses were lacking. In the current narrative review, we give an overview on the respective entities of nmCRPC and summarize novel treatment options that arose from the publication of the results of the SPARTAN and PROSPER trials and their subanalyses. We critically address the role that novel imaging modalities, namely

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIHumansMalePositron Emission Tomography Computed TomographyProstatic Neoplasms, Castration-ResistantAntigens, SurfaceGlutamate Carboxypeptidase IIApalutamideBicalutamideEnzalutamideLymph nodesMetastasis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.